Expanded hypertension screening, diagnosis, and treatment

Expanded hypertension screening, diagnosis, and treatment increases quality-adjusted life-years in silico (51.3 QALYs gained per 100,000 eligible adults).

“Universal 80-80-80 expansion averted 60.7 cardiovascular events and 6.1 cardiovascular deaths and gained 51.3 QALYs per 100,000 eligible adults.”

In silicoAdults covered by Peru's Seguro Integral de Salud; compared with population-specific usual careuniversal 80-80-80 expansion10-year modeled horizon

Cost-utility of expanded hypertension screening and treatment among adults covered by Peru's Seguro integral de salud: a markov Model using national data

Expert review of pharmacoeconomics & outcomes research·16 Oct 2026

Expanded hypertension screening, diagnosis, and treatment decreases cardiovascular deaths in silico (6.1 cardiovascular deaths averted per 100,000 eligible adults).

“Universal 80-80-80 expansion averted 60.7 cardiovascular events and 6.1 cardiovascular deaths and gained 51.3 QALYs per 100,000 eligible adults.”

In silicoAdults covered by Peru's Seguro Integral de Salud; compared with population-specific usual careuniversal 80-80-80 expansion10-year modeled horizon

Cost-utility of expanded hypertension screening and treatment among adults covered by Peru's Seguro integral de salud: a markov Model using national data

Expert review of pharmacoeconomics & outcomes research·16 Oct 2026

Expanded hypertension screening, diagnosis, and treatment decreases cardiovascular events in silico (60.7 cardiovascular events averted per 100,000 eligible adults).

“Universal 80-80-80 expansion averted 60.7 cardiovascular events and 6.1 cardiovascular deaths and gained 51.3 QALYs per 100,000 eligible adults.”

In silicoAdults covered by Peru's Seguro Integral de Salud; compared with population-specific usual careuniversal 80-80-80 expansion10-year modeled horizon

Cost-utility of expanded hypertension screening and treatment among adults covered by Peru's Seguro integral de salud: a markov Model using national data

Expert review of pharmacoeconomics & outcomes research·16 Oct 2026